title: Troglitazone stimulates beta-arrestin-dependent cardiomyocyte contractility via the angiotensin II type 1A receptor.
abstract: Peroxisome proliferator-activated receptor gamma (PPAR gamma) agonists are commonly used to treat cardiovascular diseases, and are reported to have several effects on cardiovascular function that may be due to PPAR gamma-independent signaling events. Select angiotensin receptor blockers (ARBs) interact with and modulate PPAR gamma activity, thus we hypothesized that a PPAR gamma agonist may exert physiologic effects via the angiotensin II type 1(A) receptor (AT1(A)R). In AT1(A)R-overexpressing HEK 293 cells, both angiotensin II (Ang II) and the PPAR gamma agonist troglitazone (Trog) enhanced AT1(A)R internalization and recruitment of endogenous beta-arrestin 1/2 (beta arr1/2) to the AT1(A)R. A fluorescence assay to measure diacylglycerol (DAG) accumulation showed that although Ang II induced AT1(A)R-G(q) protein-mediated DAG accumulation, Trog had no impact on DAG generation. Trog-mediated recruitment of beta arr1/2 was selective to AT1(A)R as the response was prevented by an ARB- and Trog-mediated beta arr1/2 recruitment to beta1-adrenergic receptor (beta 1AR) was not observed. In isolated mouse cardiomyocytes, Trog increased both % and rate of cell shortening to a similar extent as Ang II, effects which were blocked with an ARB. Additionally, these effects were found to be beta arr2-dependent, as cardiomyocytes isolated from beta arr2-KO mice showed blunted contractile responses to Trog. These findings show for the first time that the PPAR gamma agonist Trog acts at the AT1(A)R to simultaneously block G(q) protein activation and induce the recruitment of beta arr1/2, which leads to an increase in cardiomyocyte contractility.
authors.affiliation: Department of Pharmaceutical Sciences, Jefferson School of Pharmacy, Thomas Jefferson University, Philadelphia, PA 19107, USA. douglas.tilley@jefferson.edu
authors.forename: Douglas G
authors.initials: DG
authors.lastname: Tilley
authors.forename: Anny D
authors.initials: AD
authors.lastname: Nguyen
authors.forename: Howard A
authors.initials: HA
authors.lastname: Rockman
mesh_terms: D019390:Arrestins / Q000378:metabolism*; D002460:Cell Line; D002839:Chromans / Q000494:pharmacology*; D043802:GTP-Binding Protein alpha Subunits, Gq-G11 / Q000378:metabolism; D006801:Humans; D009200:Myocardial Contraction / Q000187:drug effects*; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000378:metabolism; D047495:PPAR gamma / Q000819:agonists*; D044140:Receptor, Angiotensin, Type 1 / Q000378:metabolism*; D045162:Thiazolidinediones / Q000494:pharmacology*; D000077288:Troglitazone; D000071559:beta-Arrestin 1; D000071560:beta-Arrestin 2; D000071557:beta-Arrestins
chemical_list: C000605253:ARRB1 protein, human; C000605254:ARRB2 protein, human; C000605255:Arrb1 protein, mouse; C000605258:Arrb2 protein, mouse; D019390:Arrestins; D002839:Chromans; D047495:PPAR gamma; D044140:Receptor, Angiotensin, Type 1; D045162:Thiazolidinediones; D000071559:beta-Arrestin 1; D000071560:beta-Arrestin 2; D000071557:beta-Arrestins; D043802:GTP-Binding Protein alpha Subunits, Gq-G11; D000077288:Troglitazone
references.citation: J Clin Invest. 2005 Mar;115(3):527-37
references.pmid: 15765134
references.citation: Br J Pharmacol. 2007 May;151(1):45-53
references.pmid: 17351653
references.citation: Science. 1999 Dec 24;286(5449):2495-8
references.pmid: 10617462
references.citation: Mol Pharmacol. 2007 Nov;72(5):1146-56
references.pmid: 17686966
references.citation: J Biol Chem. 2003 Nov 21;278(47):46261-9
references.pmid: 12966092
references.citation: J Biol Chem. 2004 Aug 20;279(34):35518-25
references.pmid: 15205453
references.citation: Exp Neurol. 2008 Jul;212(1):93-9
references.pmid: 18471812
references.citation: Am J Cardiol. 2010 Jan 4;105(1 Suppl):30A-5A
references.pmid: 20102971
references.citation: Trends Pharmacol Sci. 2007 Aug;28(8):423-30
references.pmid: 17659355
references.citation: J Biol Chem. 2009 Mar 27;284(13):8855-65
references.pmid: 19171933
references.citation: Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16657-62
references.pmid: 17925438
references.citation: J Biol Chem. 2005 Mar 18;280(11):10109-18
references.pmid: 15649892
references.citation: Circulation. 2003 Sep 30;108(13):1611-8
references.pmid: 12963634
references.citation: J Clin Invest. 2007 Sep;117(9):2445-58
references.pmid: 17786238
references.citation: Diab Vasc Dis Res. 2006 Sep;3(2):65-71
references.pmid: 17058625
references.citation: Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14555-60
references.pmid: 18787115
references.citation: Theor Biol Med Model. 2006 Jan 10;3:1
references.pmid: 16403216
references.citation: Circulation. 2002 Mar 12;105(10):1240-6
references.pmid: 11889020
references.citation: Diabetes. 2005 Dec;54(12):3442-52
references.pmid: 16306360
references.citation: Immunol Cell Biol. 2010 Mar-Apr;88(3):305-12
references.pmid: 19997078
references.citation: J Biol Chem. 2008 Jan 25;283(4):2088-97
references.pmid: 18006496
references.citation: Mol Pharmacol. 2006 Nov;70(5):1575-84
references.pmid: 16901982
references.citation: Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16284-9
references.pmid: 17060617
references.citation: Hypertension. 2004 May;43(5):993-1002
references.pmid: 15007034
references.citation: J Biol Chem. 1998 Jul 17;273(29):18180-4
references.pmid: 9660778
references.citation: J Biol Chem. 2009 Jul 24;284(30):20375-86
references.pmid: 19509284
references.citation: Annu Rev Physiol. 2007;69:483-510
references.pmid: 17305471
references.citation: Hypertension. 2006 Jan;47(1):102-8
references.pmid: 16344371
references.citation: Cardiovasc Res. 2005 Mar 1;65(4):772-81
references.pmid: 15721857
references.citation: J Biol Chem. 2006 Nov 24;281(47):36411-9
references.pmid: 17008309